CPG 10101
- Generic Name
- CPG 10101
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 957255-05-9
- Unique Ingredient Identifier
- -
- Background
CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.
- Indication
Investigated for use/treatment in hepatitis (viral, C) and viral infection.
- Associated Conditions
- -
- Associated Therapies
- -
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 113
- Registration Number
- NCT00277238
- Locations
- 🇺🇸
Pfizer Investigational Site, Richmond, Virginia, United States
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 91
- Registration Number
- NCT00142103
- Locations
- 🇺🇸
Pfizer Investigational Site, Richmond, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath